We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
The State FDA informed that the team will take the investigation up to the manufacturer’s level and also work towards identifying supply chain discrepancies.
Out of 60,000 vials, Maharashtra, which has the highest number of COVID-19 cases in the country will get 12,500 followed by Delhi and Telangana with 10,000 and 9,000 respectively.
Measures include constant monitoring of the drug’s usage and ensuring its uninterrupted supply by working in collaboration with healthcare practitioners and regulators.
COVIFOR will be available in 100 mg vial (injectable) which has to be administered intravenously in a hospital setting under the supervision of a healthcare practitioner.